| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3935357f2393110e9394b6233f8fccb3 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B01J2231-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B01J2531-16 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-715
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C08B37-006
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B01J31-0205
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B01J31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C08B37-0003 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/B01J31-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C08B37-00 |
| filingDate |
2021-01-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ac9137a8f4c9790bd43d17e35c7e2962
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_79a49cd90906c1ff900ad5583b38a5a4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c85a14a9d885fcbcf9d1d5e1f6f44dea
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_85552cdf195291275e5fbb337477cfac |
| publicationDate |
2022-02-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2022041762-A1 |
| titleOfInvention |
Low-molecular-weight tremella aurantialba glucuronoxylomannan as well as preparation method and application thereof |
| abstract |
The present disclosure provides a low-molecular-weight Tremella aurantialba glucuronoxylomannan (LTAG) as well as a preparation method and an application thereof, and specifically relates to the technical field of medicine. The LTAG provided in the present disclosure has a weight-average molecular weight of 8,000-24,000 Da. In the method of preparing LTAG as provided in the present disclosure, Tremella aurantialba glucuronoxylomannan is depolymerized by peroxides so as to get low-molecular-weight products, which are then exchanged into pharmaceutically acceptable salts through cation exchange resins. The resulting LTAG has a clear structure, a low viscosity and a good solubility, has a strong immune-enhancing activity, and is capable of acting on TLR4 receptor-activated macrophagocytes and promoting the production of various immune factors, so it can be used in the prevention and/or treatment of immunodeficiency-related diseases. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111690543-A |
| priorityDate |
2020-01-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |